Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

See preview >>

  Email address:
   

Decheng, a China Investor, Participates in Invitae's $120 Million Funding

publication date: Oct 14, 2014
Invitae Corporation, a San Francisco genetic testing company, raised a huge $120 million in a Series F funding round. One of the participants was Decheng Capital, a Shanghai-based investment company focused on life science. Decheng was spun out of San Francisco's Bay City Capital in 2011. Invitae has developed a single test for 218 genes that are associated with significant health problems. The test, which costs only $1500, provides a genetic reading in three weeks. Invitae says the new capital be used to build its infrastructure. More details....

Share this with colleagues:  


This article is available for purchase - please click here for details.

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


 

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

ChinaBio® News

Greg Scott BIO-Europe Interview
Greg Scott Interviewed at BIO-Europe Spring

How to bring your China assets to China in 8 minutes

Greg Scott Mendelspod Interview
"Mr. Bio in China."
Mendelspod Interview

Multinational pharma held to a higher standard in China

Partner Event
November 2-3, 2023 | Shanghai
November 7-8, 2023 | Digital